The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.

Jolie Bou-GhariosSahar AssiHisham F BahmadHussein KharroubiTarek ArajiReda M ChalhoubFarah BalloutHayat HaratiYoussef FaresWassim Abou Kheir

Published in: Pharmacological reports : PR (2020)

In conclusion, TDG has proven its effectiveness in targeting the cancerous properties of GBM in vitro and may, hence, serve as a potential adjuvant radio-therapeutic agent to better target this deadly tumor.

Keyphrases

early stage
randomized controlled trial
papillary thyroid
systematic review
human health
squamous cell
risk assessment
replacement therapy